Pisarenko O I, Serebriakova L I, Pelogeĭkina Iu A, Studneva I M, Kkhatri D N, Tskitishvili O V, Bespalova Zh D, Az'muko A A, Sidorova M V, Pal'keeva M E, Chazov E I
Kardiologiia. 2012;52(2):52-8.
Apelin 12 (A-12) was synthesized by the automatic solid phase method with the use of Fmoc technology. The synthesized peptide was purified by preparative HPLC and identified by 1H-NMR spectroscopy and mass spectrometry. Acute myocardial infarction was induced by 40-min LAD occlusion followed by 60-min reperfusion in narcotized Wistar rats. A-12 was administrated at the onset of the reperfusion at doses of 0.07, 0.35 and 0.70 micromole/kg; N(G)-nitro-L-arginine methyl ester (L-NAME), a NOS inhibitor, was applied at a dose of 10 mg/kg 10 min prior to reperfusion alone or before A-12 administration (0.35 micromole/kg); saline was used in control. The indicated A-12 doses induced a transient reduction of the arterial systolic blood pressure (ASBP) to 85, 58, and 56% of the initial level, respectively, which was accompanied by its recovery by the end of reperfusion. All A-12 doses significantly limited myocardial infarct size by 26, 40 and 33%, respectively, compared to the value in control. After administration of A-12 at dose of 0.35 micromol/kg, this effect was combined with reduction of MB-creatine kinase (MB-CK) and lactate dehydrogenase (LDH) activities in plasma at the end of reperfusion by 56 and 47%, respectively, compared to the values in control. Inhibition of NO formation by L-NAME increased SABP but did not affect myocardial infarct size compared with that in control. Coadministration of L-NAME and A-12 resulted in lesser reduction of ASBP during reperfusion than injection of A-12 alone. This intervention led to an increase in infarct size by 26% with concomitant 1.8- and 1.5-times elevation of MB-CK and LDH activities, respectively, compared to the values in the A-12 group. The results indicate that NO is involved as a mediator of the effects of A-12 on the overall protection consisting in a limitation of infarct size and reduction of postischemic cardiomyocyte membrane damage. Cardioprotective mechanisms of apelin action are discussed.
采用Fmoc技术通过自动固相法合成阿片肽12(A - 12)。合成的肽通过制备型高效液相色谱法纯化,并通过1H - NMR光谱和质谱进行鉴定。在麻醉的Wistar大鼠中,通过结扎左冠状动脉前降支40分钟,随后再灌注60分钟诱导急性心肌梗死。在再灌注开始时,以0.07、0.35和0.70微摩尔/千克的剂量给予A - 12;单独在再灌注前10分钟或在给予A - 12(0.35微摩尔/千克)之前,以10毫克/千克的剂量应用一氧化氮合酶(NOS)抑制剂N(G)-硝基-L-精氨酸甲酯(L-NAME);对照组使用生理盐水。所示的A - 12剂量分别使动脉收缩压(ASBP)短暂降低至初始水平的85%、58%和56%,并在再灌注结束时恢复。与对照组相比,所有A - 12剂量均使心肌梗死面积显著缩小,分别缩小26%、40%和33%。在以0.35微摩尔/千克的剂量给予A - 12后,与对照组相比,这种作用还伴随着再灌注结束时血浆中肌酸激酶同工酶(MB - CK)和乳酸脱氢酶(LDH)活性分别降低56%和47%。与对照组相比,L-NAME抑制NO生成增加了收缩压,但不影响心肌梗死面积。L-NAME和A - 12联合给药导致再灌注期间ASBP的降低幅度小于单独注射A - 12。与A - 12组相比,这种干预导致梗死面积增加26%,同时MB - CK和LDH活性分别升高1.8倍和1.5倍。结果表明,NO作为A - 12对整体保护作用(包括限制梗死面积和减少缺血后心肌细胞膜损伤)的介导因子发挥作用。文中还讨论了阿片肽作用的心脏保护机制。